Narinder Malhotra, MD
Medical Oncology · Meadville, PANPI 1942207337
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,152 of the $1,393 with a category attached, or 82.7%. It is spread thinly across 26 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for medical oncology clinicians in PA, where the typical reported total is $2,595.
Across 66 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$321
- E.r. Squibb & Sons, L.L.C.$150
- Incyte Corporation$118
- Merck$102
- Sanofi-aventis U.S. LLC$100
- Rigel Pharmaceuticals, Inc.$82
- plus $521 from 20 others
What the payments were for
- Food & beverage$1,15283%
- Education$24117%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $321 |
| E.r. Squibb & Sons, L.L.C. | 12 | $150 |
| Incyte Corporation | 2 | $118 |
| Merck | 5 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Rigel Pharmaceuticals, Inc. | 4 | $82 |
| Eisai Inc. | 1 | $52 |
| Bayer | 3 | $50 |
| Novartis | 2 | $37 |
| AstraZeneca | 2 | $36 |
| Karyopharm Therapeutics Inc. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| EMD Serono, Inc. | 1 | $27 |
| Exelixis Inc. | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $25 |
| Sobi, Inc | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Array Biopharma Inc | 1 | $20 |
| Myovant Sciences Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $19 |
| Adaptive Biotechnologies Corporation | 1 | $18 |
| Astellas Pharma US Inc | 1 | $15 |
| Acceleron Pharma, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,393 in reported general payments places this provider in the 40th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 17 | $206,562 |
| VenclextaVenetoclax | 14 | $46,769 |
| Anastrozole | 12 | $149 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Meadville
- Carl JunePhiladelphia$9M
- Adam BrufskyPittsburgh$1.3M
- Sramila AithalBensalem$682K
- Shayma KazmiPhiladelphia$619K
- Deric SaviorWynnewood$343K
- Marcia BrosePhiladelphia$260K
- Adam CohenPhiladelphia$239K
- Daniel HallerPhiladelphia$227K
- Edith MitchellPhiladelphia$220K
- Elizabeth PlimackPhiladelphia$190K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.